Literature DB >> 11796838

Correlation of tissue inhibitor of metalloproteinase-2 with proliferative activity and patients' survival in breast cancer.

Lydia Nakopoulou1, Sophia Katsarou, Ioanna Giannopoulou, Paraskevi Alexandrou, Ioanna Tsirmpa, Effie Panayotopoulou, Johnny Mavrommatis, Antonios Keramopoulos.   

Abstract

Tissue inhibitors of metalloproteinases (TIMPs) are endogenous regulators of matrix metalloproteinases (MMPs). They are believed to possess several distinct cellular functions, particularly the contradictory activities of inhibiting MMPs and promoting tumor cell growth. Immunohistochemistry was performed to detect TIMP-2 protein in 136 infiltrative breast carcinomas. TIMP-2 protein was analyzed in parallel with clinicopathologic features (tumor size, histologic type, nuclear and histologic grade, stage), patients' overall survival and ER, PR, Ki-67, topo IIalpha, c-erbB-2, p53 and bcl-2 proteins. Statistical analysis was performed using univariate and multivariate models analysis. Immunoreactivity for TIMP-2 was observed in cancer cells and stromal fibroblasts in 106 (77.94%) and 104 (76.47%) of 136 cases, respectively. TIMP-2 protein expression in stromal fibroblasts showed a statistically significant inverse correlation with tumor size (P =.014). An inverse correlation was also observed between TIMP-2 epithelial immunoreactivity and nuclear and histologic grade (P =.036 and P =.007, respectively). TIMP-2 protein reactivity showed statistically significant positive associations with topo IIalpha and bcl-2 in stromal and cancer cells, respectively (P =.032 and P =.001, respectively). TIMP-2 protein expression in cancer and stromal cells was associated with better patients' overall survival (P =.002 and P =.038, respectively). When evaluated by the Cox's proportional hazard regression model, this association was further established, but only as far as TIMP-2 expression in tumor epithelium was concerned (P =.019). Our results support the multifunctional potential of TIMP-2 through its correlation on the one hand to a favorable outcome, due to its MMP inhibitory activity and on the other to topo IIalpha contributing to its growth factor activity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11796838     DOI: 10.1038/modpathol.3880486

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  8 in total

Review 1.  The Roles of Matrix Metalloproteinases and Their Inhibitors in Human Diseases.

Authors:  Griselda A Cabral-Pacheco; Idalia Garza-Veloz; Claudia Castruita-De la Rosa; Jesús M Ramirez-Acuña; Braulio A Perez-Romero; Jesús F Guerrero-Rodriguez; Nadia Martinez-Avila; Margarita L Martinez-Fierro
Journal:  Int J Mol Sci       Date:  2020-12-20       Impact factor: 5.923

2.  Tissue inhibitor of matrix metalloproteinase-2 in nasopharyngeal carcinoma.

Authors:  Amr Ahmed El Badry; Amal Abou El-Fadle; Abdel Latif El-Balshy
Journal:  MedGenMed       Date:  2007-07-03

3.  Breaking down bone: new insight into site-specific mechanisms of breast cancer osteolysis mediated by metalloproteinases.

Authors:  Theresa A Guise
Journal:  Genes Dev       Date:  2009-09-15       Impact factor: 11.361

4.  Expression and functional properties of antibodies to tissue inhibitors of metalloproteinases (TIMPs) in rheumatoid arthritis.

Authors:  Maria Bokarewa; Leif Dahlberg; Andrej Tarkowski
Journal:  Arthritis Res Ther       Date:  2005-06-22       Impact factor: 5.156

5.  MMP-9 and MMP-2 gelatinases and TIMP-1 and TIMP-2 inhibitors in breast cancer: correlations with prognostic factors.

Authors:  D C Jinga; A Blidaru; Ileana Condrea; Carmen Ardeleanu; Cristina Dragomir; G Szegli; Maria Stefanescu; Cristiana Matache
Journal:  J Cell Mol Med       Date:  2006 Apr-Jun       Impact factor: 5.310

6.  Immunoreactivity for TIMP-2 is associated with a favorable prognosis in endometrial carcinoma.

Authors:  Maria Honkavuori-Toivola; Anne Talvensaari-Mattila; Ylermi Soini; Taina Turpeenniemi-Hujanen; Markku Santala
Journal:  Tumour Biol       Date:  2012-01-21

7.  Tissue inhibitor of metalloproteinase-1 stimulates proliferation of human cancer cells by inhibiting a metalloproteinase.

Authors:  J F Porter; S Shen; D T Denhardt
Journal:  Br J Cancer       Date:  2004-01-26       Impact factor: 7.640

Review 8.  Markers of breast cancer stromal fibroblasts in the primary tumour site associated with lymph node metastasis: a systematic review including our case series.

Authors:  Maria Aparecida Azevedo Koike Folgueira; Simone Maistro; Maria Lucia Hirata Katayama; Rosimeire Aparecida Roela; Fiorita Gonzales Lopes Mundim; Suely Nanogaki; Geertruida H de Bock; M Mitzi Brentani
Journal:  Biosci Rep       Date:  2013-12-12       Impact factor: 3.840

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.